If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
185
results.
Updated on
20/08/2026 [07:53:00]
Absstract of: EP4792890A2
0001 The present invention relates to fused piperidinyl bicyclic, meta-substituted piperidinyl and their related compounds that modulate activities of mammalian C5a receptor by directly binding to the C5a receptor. The invention also relates to pharmaceutical compositions containing such compounds and their use in the treatment of a disease or a disorder involving pathogenic activation of C5a receptors.
Absstract of: EP4793289A2
The present invention relates to proteins, particularly antibodies such as anti-CD20/anti-CD3 bispecific antibodies and anti a-synuclein antibodies, having monogalactosylated (Gl) and digalactosylated (G2) glycans. More particular, the present invention relates to galactosylation engineering to generate proteins with improved therapeutic properties, including proteins with increased titer. Further, the invention relates to a cell culture medium and a mammalian cell as well as methods using said cell culture medium and said mammalian cell for producing said proteins. Moreover, the present invention relates to the use of said antibodies as a medicament such as for the treatment of cancer, particularly cancer associated with B-cells, or Parkinson's disease.
Absstract of: EP4793283A1
The present invention belongs the field of biomedicine, namely, treating and preventing Parkinson's and Alzheimer's diseases. These diseases are characterized by the presence of amyloid fibrils that drive the pathology progression in the brains of affected individuals. The invention discloses peptides that block ends of amyloid fibrils and stop their growth.
Absstract of: WO2025078660A1
An isolated protein comprising (i) a first protein moiety selected from the group of proteins comprising an amino acid sequence having at least 70% identity to residues 113-231 of Bri2 from human (SEQ ID NO: 2); and proteins comprising an amino acid sequence having at least 70% identity to any one of the BRICHOS domains of Bri2 from human (SEQ ID NO: 5), chimpanzee (SEQ ID NO: 6), bovine (SEQ ID NO: 7), pig (SEQ ID NO: 8), mouse (SEQ ID NO: 9) and rat (SEQ ID NO: 10); and and optionally (ii) a second protein or polypeptide moiety, preferably containing at least 50 amino acid residues, wherein the second protein or polypeptide moiety is selected from the group consisting of protein drugs, polypeptide drugs, antibodies and/or neurotrophic factors; wherein the second protein or polypeptide moiety is effective for treatment of Parkinson's Disease; for use as a medicament, in particular for treatment of Parkinson's Disease.
Absstract of: AU2024411063A1
Disclosed are compounds of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed are a medicament and a pharmaceutical composition comprising said compounds of formula (I), and said compounds (I) for use in the treatment of a neurodegenerative disease such as Parkinson's disease. Further disclosed are a solid form of a compound of Formula (I-a), characterized as crystalline Form A, as well as a pharmaceutical composition comprising said solid form, and said solid form for use in treating a neurodegenerative disease.
Absstract of: AU2025229421A1
Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.
Absstract of: WO2026170050A1
In one aspect, the present invention provides nucleic acids encoding T cell receptor alpha and beta chains which can associate with each other in order to form functional T cell receptors (TCRs) specific for cryptic epitopes of, for example, HDGFL2 protein, IgLON5 protein and others expressed by a target cell. In other aspects, the invention provides T cell receptors (TCRs) specific for cryptic epitopes, modified T cells expressing the T cell receptors, methods for generating the modified T cells, and diagnostic/screening methods for identifying subjects expressing TCRs comprising antigen specificities for cryptic peptides associated with TDP-43 proteinopathies. In further aspects, the invention provides a method for stimulating an immune response, treating a subject with a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS) or inclusion body myositis (IBM), and detecting a TDP-43 proteinopathy-associated immune signature in a subject.
Absstract of: US20260232655A1
This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Absstract of: WO2026165656A1
Provided is a compound of formula 1, wherein X is O or S and R is an electrophilic warhead group that comprises nitrile, a boronic ester or an a-ketoamide motif. Said compound is a prolyl oligopeptidase inhibitor that is useful in the treatment of Alzheimer's disease or Parkinson's disease and for inhibiting autophagy. (I)
Absstract of: WO2026167384A1
The invention relates to a combination of active agents consisting of three herbal extracts, which can be used in the prevention or treatment of neurodegenerative diseases, in particular glaucoma, Parkinson's disease and diabetic retinopathy. The invention also relates to compositions comprising the combination of active agents and a method for preventing or treating neurodegenerative diseases, which method comprises administering the combination of active agents to a subject in need thereof. The invention also relates to compositions comprising the combinations of active agents. The combination of active agents comprises extracts of Rosmarinus officinalis, Foeniculum vulgare and Helichrysum italicum.
Absstract of: AU2024424105A1
The present invention provides a novel Kv1.3 channel (or Kv1.3) inhibitor, which can be used for preventing and/or treating Kv1.3 channel (or Kv1.3)-related diseases, including immune and inflammatory diseases, such as multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, type I diabetes, psoriasis and asthma, spondylitis and periodontitis; and obesity, type 2 diabetes, renal fibrosis, Alzheimer's disease, and ischemic stroke.
Absstract of: US20260235628A1
0000 U-p53 peptide P1 is useful in the determination of the rate of progression of Alzheimer's disease (AD). By quantitating the level of U-p53 peptides in a subject's biological sample, the rate of progression of Alzheimer's disease at the pre-clinical and prodromal stages of the disease in a subject can be determined.
Absstract of: WO2026167653A1
Presented herein are methods, systems, and a model useful in identifying a subject who has, or is at risk of developing Alzheimer's Disease (AD) and/or Mild Cognitive Impairment (MCI), or identifying a subject who has or is at risk of progressing from MCI to AD, or increasing in the severity of AD symptoms that includes determining a presence or amount of two or more micro-RNAs (miRNAs) selected from 151a-3p, 151a-5p, 146a-5p, 4454, 10b-5p, 199a-3p, 199a-5p, 29b-3p, 126-5p, 150-5p, 107, let-7g-5p, 1290, 95-3p, 375- 3p, 99a-5p, 125b-5p, 642a-5p, 92a-1-5p, 362-5p, 342-3p, 196a-5p, 155-5p, 409-3p, 744-5p, 223-3p, 584-5p, 340-5p, 421, 486-5p, 126-3p, 320c, 320b, let-7d-3p, 27b-3p, 148b-3p, 143- 3p, 326, 335-5p, 25-3p, 153-3p, 19b-3p, let-7c-5p, 652-3p, 376c-3p, 154-5p, 376a-3p, 30d- 5p, and 381-3p in a subject's circulating blood, without determining a presence or amount of the miRNAs from neural-derived exosomes. Also presented herein are methods of preventing, treating, or delaying the onset of AD and/or MCI.
Absstract of: AU2025207266A1
Described are Microtubule-associated protein tau (MAPT) antisense oligonucleotides (ASOs) and MAPT ASO conjugates, and methods of using the MAPT ASOs and MAPT ASO conjugates to treat neurodegenerative disorders, such as Alzheimer's disease.
Absstract of: WO2025076156A1
This invention provides a method for determining whether a human subject is afflicted with Alzheimer's disease ("AD") or non-Alzheimer's dementia ("non-ADD") when the subject is suspected of being afflicted with AD or non-ADD, comprising the steps of (a) synchronizing a population of suitable cells derived from the subject, wherein the suitable cells are cultured skin cell fibroblasts or cultured B lymphocytes; and (b) in the resulting synchronized cell population, measuring the expression levels of two or more genes selected from the group consisting of FAM149B, NHLH1, SHISA5, URB2, and WASF2, whereby (i) the subject is afflicted with AD if the expression levels measured in step (b) are consistent with those genes' expression levels in corresponding synchronized cells derived from AD patients, and (ii) the subject is afflicted with non-ADD if the expression levels measured in step (b) are consistent with those genes' expression levels in corresponding synchronized cells derived from non-ADD patients. This invention also provides related diagnostic and therapeutic methods, including diagnostic methods based on NDS subject gene expression levels.
Absstract of: TW202530208A
The present disclosure relates to transcription modulator molecules having a first terminus, a second terminus, and an oligomeric backbone and methods for treating Huntington's disease (HD).
Absstract of: WO2025076219A1
The present disclosure relates to transcription modulator molecules having a first terminus, a second terminus, and an oligomeric backbone and methods for treating Huntington's disease (HD).
Absstract of: GB2703800A
The invention relates to eight synthetic compounds related to naturally occurring flavonoids such as 7,8-dihydroxyflavone (7,8-DHF): The invention further relates to the synthesis of these piperidinyl chromeno7,8-dimidazol-6(3H)-one and piperidinyl chromeno7,8-dimidazol-6(1H)-one compounds, the use of these piperidinyl compounds as research tools, their use as pharmaceuticals, and to intermediates in their synthesis. These compounds may be useful in the treatment of conditions such as depression and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). See Table 1
Absstract of: GB2703823A
AAV vectors which encode for DNAJB1, particularly of a AAV9 serotype or variant thereof are claimed. The AAV vectors are used in a method of treatment of a disease, wherein the disease is ALS and/or FTD, a disease characterised by production of one or more dipeptide repeat proteins, or a disease characterised by TDP-43 mislocalization or TDP-43 proteinopathy. none
Absstract of: WO2025076181A1
The present disclosure relates to transcription modulator molecules having a first terminus, a second terminus, and an oligomeric backbone and methods for treating Huntington's disease (HD).
Absstract of: CN121969615A
The present invention relates to carbamate compounds of formula (I), as further detailed herein, for use in inhibiting the SARM1 protein, as well as compositions comprising these compounds and methods of treatment by administration of the compounds and compositions.
Absstract of: WO2025076088A1
This invention relates to lactam compounds of Formula (I), as further detailed herein, which are used for inhibition of SARM1 proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
Absstract of: US20260224561A1
0000 The disclosure provides compounds, in part, compounds of Formula I or Formula II and their use in treating medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and methods of making compounds of the disclosure are provided. The compounds are contemplated to be modulators, e.g., inhibitors, of cyclic ADP ribose hydrolase (CD38).
Absstract of: AU2025213908A1
A compound specifically binding to an α-synuclein aggregate, and a preparation method therefor and the use thereof. Specifically, the compound binding to the α-synuclein aggregate comprises compounds as shown in formula A or sub-general formulas thereof, or stereoisomers, pharmaceutically acceptable salts, solvates or stable isotope variants thereof. The compound is a small molecule tracer, which can specifically recognize the α-synuclein aggregate, and can be used for the preparation of a drug for the treatment or diagnosis of neurodegenerative diseases (such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy and progressive muscular atrophy) related to the α-synuclein aggregate and other misfolded proteins.
Nº publicación: US20260226036A1 06/08/2026
Applicant:
UNIV OF NORTH TEXAS HEALTH SCIENCE CENTER [US]
UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER
Absstract of: US20260226036A1
Provided herein are compounds of the formula wherein the variables are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, the compounds or compositions of the present disclosure may be used for the treatment of diseases or disorders, such as an addiction or neurodegenerative disease including Alzheimer's disease or Parkinson's disease.
BOPI
Electronic site
